Related Experiment Video

Updated: Apr 12, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K

Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: a systematic review

Antonino Grassadonia1, Marta Caporale2, Nicola Tinari1

  • 11. Department of Medical, Oral and Biotechnological Sciences, University "G. D'Annunzio", Chieti, Italy ; 2. Medical Oncology Unit, "SS. Annunziata" Hospital, Chieti, Italy.

Journal of Cancer
|May 23, 2015
PubMed

Insights

Combining endocrine therapy with targeted agents in advanced breast cancer did not significantly improve response rates compared to endocrine therapy alone. Further research is needed to identify effective combination strategies for HR-positive breast cancer.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Hormone receptor-positive (HR+) advanced breast cancer often involves aberrant signaling pathways.
  • Targeting these pathways alongside endocrine therapy may improve treatment efficacy.

Purpose of the Study:

  • To systematically review clinical trials investigating the combination of endocrine therapy and targeted agents in the neoadjuvant setting for HR-positive advanced breast cancer.
  • To assess if combining endocrine agents with targeted therapies improves clinical response rates.

Main Methods:

  • Systematic review of the Pubmed database.
  • Inclusion of nine Phase II clinical trials evaluating endocrine agents (aromatase inhibitors) combined with targeted agents.
  • Exclusion of preclinical studies and trials focused solely on toxicity.

Main Results:

  • Response rates for combination therapies ranged from 36% to 90%.
  • The combination of endocrine therapy with targeted agents did not demonstrate a remarkable advantage in response rate compared to historical controls receiving aromatase inhibitors alone.

Conclusions:

  • Current evidence suggests that combining third-generation aromatase inhibitors with various targeted agents does not significantly enhance response rates in the neoadjuvant setting for HR-positive advanced breast cancer.
  • Further investigation is warranted to identify specific targeted agents or patient subgroups that may benefit from combination therapy.
Keywords:
breast cancerclinical responseneoadjuvant endocrine therapytargeted therapy

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

7.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K